JP Morgan Initiates Coverage On Seaport Therapeutics with Overweight Rating, Announces Price Target of $42

Benzinga Newsdesk www.benzinga.com Positive 51.8%

Neg 0% Neu 0% Pos 51.8%

JP Morgan analyst Tessa Romero initiates coverage on Seaport Therapeutics (NASDAQ:SPTX) with a Overweight rating and announces Price Target of $42.